OptiBiotix Health's subsidiary inks Japanese licensing agreement
OptiBiotix Health's fully-owned subsidiary ProBiotix Health expanded its reach in Asia on Wednesday as it signed a non-exclusive license agreement with Tenshindo for the use of lactobacillus plantarum LPLDL in cardiovascular food supplements in Japan.
FTSE AIM All-Share
745.67
17:08 19/04/24
OptiBiotix Health
18.00p
16:55 19/04/24
Pharmaceuticals & Biotechnology
21,247.91
17:09 19/04/24
The agreement is the first end product application deal stemming from ProBiotix's agreement with Japanese distributor EIWA Trading Corporation and will see Tenshindo make a new health product with LPLDL as the active ingredient.
The two companies will also work together to obtain an authorised cardiovascular health claim for LPLDL from the Japanese authorities, based on the existing clinical and market evidence on the strain.
Founded in 1986, Tenshindo is a manufacturer of functional food and cosmetics products that has a portfolio of over 50 products.
Luis Gosalbez, business development director of OptiBiotix, said: "We are pleased to announce this deal with Tenshindo, which will mean our first LPLDL finished product placement on the Japanese market. Obtaining an authorised cardiovascular health claim for LPLDL from Japanese authorities will not only be highly advantageous from the commercial point of view, but also an important endorsement for ProBiotix's science."
Optibiotix Health's shares were up 0.91% at 83.25p at 1243 BST.